TFF Pharmaceuticals Inc (TFFP)
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN Summary
TFFP Chart
TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why
TFF Pharmaceuticals (TFFP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
TFF Pharmaceuticals, Inc. (TFFP) Reports Q2 Loss, Tops Revenue Estimates
TFF Pharmaceuticals, Inc. (TFFP) came out with a quarterly loss of $1.22 per share versus the Zacks Consensus Estimate of a loss of $1.70. This compares to loss of $3.50 per share a year ago.
TFF Pharmaceuticals Inc (TFFP) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
TFF Pharmaceuticals Inc Profile
| - Industry | - Sector | Dr. Harlan F. Weisman CEO | NASDAQ (CM) Exchange | 87241J104 CUSIP |
| US Country | 19 Employees | - Last Dividend | 19 Dec 2023 Last Split | 25 Oct 2019 IPO Date |
Overview
TFF Pharmaceuticals, Inc. is a pioneering biopharmaceutical company engaged in the clinical stage development and commercialization of drug products. Leveraging its patented Thin Film Freezing (TFF) technology platform, the company aims to revolutionize treatment methods in the United States and Australia by focusing on the creation of inhaled dry powder drugs. These innovative drugs are primarily targeted at treating various pulmonary diseases and conditions. Incorporated in 2018 and based in Fort Worth, Texas, TFF Pharmaceuticals, Inc. is at the forefront of transforming drug delivery methods through its strategic partnerships and licensing agreements with notable organizations such as the University of Texas at Austin, Augmenta Bioworks, Inc., UNION therapeutics A/S, and the National Institute of Environmental Health Sciences.
Products and Services
- TFF Voriconazole Inhalation Powder
- TFF Tacrolimus Inhalation Powder
- Augmenta Monoclonal Antibodies
- TFF Niclosamide
- Other Vaccines and Therapeutics
Currently in Phase II clinical trials, this leading drug candidate is designed to treat invasive pulmonary aspergillosis, a serious condition that affects the lungs. By utilizing the TFF technology, Voriconazole is transformed into an inhalable dry powder, making it potentially more effective and easier to administer.
Also in Phase II clinical trials, TFF Tacrolimus aims to prevent lung transplant rejection. This inhalation powder form of tacrolimus represents an innovative approach to immunosuppressive therapy, potentially improving outcomes for lung transplant recipients.
In collaboration with Augmenta Bioworks, Inc., TFF Pharmaceuticals is developing monoclonal antibodies for the treatment of COVID-19. These antibodies leverage the TFF platform to create inhalable powders, aiming to offer a novel therapeutic option for COVID-19 patients.
Completing Phase 1 clinical trials, TFF Niclosamide targets the treatment of COVID-19 disease. By formulating Niclosamide as a dry powder inhalant, it is envisaged to offer a more direct and potentially effective treatment modality against the virus.
Expanding its portfolio, TFF Pharmaceuticals is actively developing other dry powder products, including vaccines. These are formulated through its TFF technology, aiming to provide innovative solutions for a variety of health conditions beyond its current focus areas.
